Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
864953-29-7
Molecular formula
C25H26N7O8P
Molecular weight
583.5 g/mol
Drug class
HIV-1 attachment inhibitorprodrug of temsavir
Mechanism of action
Fostemsavir is hydrolysed to temsavir, which binds the gp120 subunit of the HIV-1 envelope glycoprotein and prevents viral attachment to the CD4 receptor, blocking an early step in viral entry.
Indications / reported uses
Treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 for whom the current antiretroviral regimen is failing due to resistance, intolerance or safety considerations, in combination with other antiretroviral agents
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fostemsavir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fostemsavir Permitted Daily Exposure (PDE) report (the Fostemsavir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fostemsavir Occupational Exposure Limit (OEL) report (the Fostemsavir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.